ArticleEuropean journal of haematology2025

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.